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Abstract 
Current trends in regenerative medicine treatments for bone repair applications focus 
on cell-based therapies.  These aim to deliver the treatment via a minimally invasive 
injection to reduce patient trauma and to improve efficacy. This paper describes the 
injectability of porous calcium phosphate glass microspheres to be used for bone 
repair based on their formulation, rheology and flow behavior.  The use of excipients 
(xanthan gum, methyl cellulose and carboxyl methyl cellulose) were investigated to 
improve flow performance.  Based on our results, the flow characteristics of the glass 
microsphere pastes vary according to particle size, surface area, and solid to liquid 
ratio, as well as the concentration of viscosity modifiers used. The optimal flow 
characteristics of calcium phosphate glass microsphere pastes was found to contain 
40 mg/mL of xanthan gum which increased viscosity whilst providing elastic 
properties (~ 29000 Pa) at shear rates that mirror the injection process and the 
resting period post injection, preventing the glass microspheres from both damage 
and dispersion.  It was established that a base formulation must contain 1g of glass 
microspheres (60 - 125 µm in size) per 1 mL of cell culture media, or 0.48g of glass 
microspheres of sizes between 125 and 200 µm.  Furthermore, the glass 
microsphere formulations with xanthan gum were readily injectable via a syringe-
needle system (3-20 mL, 18G and 14G needles), and have the potential to be 
utilized as a cell (or other biologics) delivery vehicle for bone regeneration 
applications.  
Keywords: Osteoporosis, bone regeneration, minimal invasive technology, 
injectable paste, porous microspheres 
1. Introduction 
Osteoporosis is a disease that reduces bone density deteriorating its internal 
microstructure and increasing the risk of fracture.  People over 65 are at higher risk of 
developing osteoporosis with more than 22 million being affected in the EU.1 Women 
are significantly affected by osteoporosis as a consequence of the menopause. In the 
UK, statistics indicate that 1 in 2 women over 50 experience osteoporotic fractures in 
comparison to 1 in 5 men.1,2 The most common and more debilitating fractures occur 
in hips accounting for 70% in women and 20% in men, with high index of mortality 
within six months after fracture.3-5  One of the most frequent drug treatments for 
osteoporosis patients includes the administration of bisphosphonates which have 
been reported to be highly effective in reducing the risk of hip fractures (~30-50%). 
However, patients receiving this drug treatment still suffer subsequent fractures within 
3 years.4, 6-11 Therefore, recent alternative approaches to promote bone healing 
explore the use of biomaterials and cell-based therapy to improve biocompatibility.12-
14 Stem cells have already shown their capability in regenerating new bone;15-17 
however, the fragility of stem cells requires a robust technology to protect them during 
transplantation and within the timeframe for regeneration of the damaged bone. 
Recently, Hossain et al. (2018) developed an innovative approach to manufacture 
porous glass microspheres produced from calcium phosphates, a key component in 
bones, which have shown efficacy to incorporate stem cells within their porous 
structure.18 One of the key suggested advantages of microspheres over irregular-
shaped materials is their potential ability to enhance flow properties, which combined 
with their microscale size could enable their delivery via minimally invasive injection 
procedures.19  In addition, calcium phosphate (CaP) glasses have been widely 
investigated for hard tissue engineering applications.20-24 The main benefit of CaP 
glasses is their degradability and controllable resorption profiles, which can be tailored 
from days to months by simply altering their composition.25 Moreover, the porous 
morphology showed to be hugely beneficial in accommodating cells, thus providing 
the potential to incorporate drugs, growth factors and other biological components with 
the aim to release on demand.26   
Furthermore, recent studies have evaluated the biocompatibility and osteogenic 
potential of CaP microspheres mixed with autologous bone marrow concentrate 
(BMC) in a large animal model (sheep).27 Histological results showed the formation of 
a collagen-enriched matrix and mineralization of the tissue within the defect after 13 
weeks post-implementation, suggesting commitment toward the bone lineage. 
However, incorporating BMC within the CaP glass microspheres did not show any 
significant differences in the histology results in comparison to microspheres implanted 
alone. In this in-vivo study, the surgical procedure included anesthetization, creation 
of a cylindrical bone defect of 8 mm width x 15 mm depth into cancellous bone of 
medial femoral condyles, then filling with glass microspheres loaded with autologous 
stem cells followed by suturing the skin. In order to reduce the use of this type of 
complicated and traumatic surgical intervention, a minimally invasive procedure is 
always preferred, such as injection of the material using a syringe in the area of 
interest. 
In this study, the formulation, rheology, flow behavior and injectability of these porous 
CaP glass microspheres along with various viscosity modifiers (such as, xanthan gum, 
methyl cellulose and carboxyl methyl cellulose) via syringe needles (14G and 18G) 
has been explored. Moreover, non-porous CaP microspheres in combination with 
porous microspheres were also evaluated to increase the load of ions as well as to 
include additional mechanical load bearing support in the formulation paste. Thus, this 
CaP formulation paste can be combined with cell-based therapies that would allow 
injecting them via a small hole into the bones of those at risk of fracture to provide a 
localized increase in bone density. 
 
2. Materials and methodology 
2.1. Microsphere manufacture 
The microspheres consisted of calcium phosphate-based glass formulation 40 P2O5 -
16 CaO -24 MgO- 20 Na2O (in mol%). They were prepared via melting quenching 
process using precursors NaH2PO4, CaHPO4, MgHPO4 and P2O5. The glass 
produced was further processed to achieve porosity (or non-porosity) and spherical 
morphology using a flame spheroidization process.18 Morphology of the CaP glass 
microspheres was determined using scanning electron microscope (SEM). The CaP 
glass microspheres were imaged under low vacuum without a coating using a FEI 
Quanta 650 environmental scanning electron microscope (Oxford Instruments INCA 
350 EDX system/80mm X-Max SDD detector, EBSD and KE Centaurus EBSD 
system).  Porosity () was calculated from the absolute density (ρabs, helium gas 
pycnometer method) and apparent density (ρapp, mass in 10 mL cylinder) using Eq 
1.28,29  
= (ρabs-ρapp)/ ρabs  Eq 1  
2.2.  Preparation of microsphere pastes (injectable technology) 
CaP glass microsphere pastes were prepared using two particle size ranges (60-125 
µm and 125-200 µm) of gamma sterilized porous and non-porous microspheres. In 
this work the main interest was to test the injectability of porous microspheres to 
allow the transport of stem cells inside the porous; however, some tests were also 
performed with the inclusion of non-porous microspheres to increase the 
concentration of ions.  We used cell culture media (DMEM Dulbecco's Modified 
Eagle, ThermoFisher Scientific) for the data presented in this paper; however, we 
also tested the optimal formulation with saline solution (0.9% NaCl) to evaluate if the 
flow behavior was maintained. To formulate an injectable CaP glass microsphere 
paste, it was necessary to use aqueous compatible excipients to mediate the 
delivery of this new glass material. We tested gamma sterilized xanthan gum (XG, 
Sigma-Aldrich), sodium carboxyl methyl cellulose (CMC, MW 250000 (DS=0.7), 
Acros Organics) and methyl cellulose (MC, Sigma-Aldrich).  They were selected from 
a list of ten candidates based on their viscosity and elasticity properties when 
dispersed in solution; however, their stability as a function pH and temperature were 
also considered. 30-33   Sterilization was achieved using gamma irradiation (Cobalt 60, 
dose 25-35 kGy) as a standard procedure in orthopedics. Furthermore,   we also 
tested hyaluronic acid (HA, MP Biomedicals) and polyethylene glycol (PEG8000, Alfa 
Aesar). However, as both HA and PEG failed to improve the flow properties of the 
paste, they were discarded during preliminary tests. To date, any of these excipients 
have not been tested in humans; however, XG has been injected in rabbits and rats 
to treat osteoporosis conditions.34-35  
The formulations were tested and optimized, the loading of solids in the carrier 
solution (solid to liquid ratio, S/L) were quantified as grams per milliliter (g/mL).  
2.3.  Rheology 
The rheological characteristics of the microsphere pastes were assessed through 
measurements of viscosity and viscoelasticity using a rheometer (Kinexus Pro, 
Malvern Instruments).  For the viscosity measurements, excipient solutions in DMEM 
were evaluated at concentrations between 20 and 80 mg/mL. Pastes composed of 
CaP glass microspheres (60-125 µm, 125-200 µm or a mixture of both size ranges), 
with DMEM, and excipient were also evaluated for viscosity. All viscosity 
measurements were performed at 20°C. 
The viscoelasticity was monitored through examining the elastic component (G’), 
viscous component (G”) and phase angle ().  G’ relates to the degree of elasticity of 
the material whereas G” measures the degree of viscosity. The crossover point 
provides a measure of the point where behavior switches from liquid-like to solid-like 
properties. The rheometer was used in oscillatory mode and a sinusoidal shear 
stress was applied to the microsphere pastes to measure deformation. Using this 
approach, a strain sweep was first performed to determine the linear region of 
viscoelasticity (LVER), then the limit of LVER was used to perform a frequency 
sweep test in which G’ and G” were quantified as a function of angular frequency 
(ω). The systems evaluated for viscoelasticity consisted of CaP glass microspheres 
(125-200 µm), DMEM and excipient.   The measurements were performed at 20°C 
and 37°C to mimic conditions of injection and post-injection. 
2.4.  Injection of microsphere pastes 
Luer-lock syringes of 3, 5, 10 and 20 mL (BDTM PastipakTM of internal diameter 8.66 
mm, 12.06 mm, 14.5 mm, 19.13 mm, respectively) were connected to either a 14G 
needle (1.6 mm internal diameter by 15 mm length) or 18G needle (0.84 mm internal 
diameter by 15 mm length). The microsphere pastes were prepared according to the 
formulations previously defined and loaded into the syringes. Trapped air was 
effectively removed using a locking syringe plunger whilst flicking the syringe.  The 
syringes were mounted for extrusion in a compression tester (Instron 5566 Test 
Bench).  The force (N) required for the extrusion of the paste was determined over a 
plunger displacement of 20 mm at a rate of 20 mm/min.  The pressure (MPa) was 
calculated by dividing the force (N) by the cross section of the area (mm2) of the 
syringe. 
3. Results 
3.1. Microsphere characteristics 
SEM analyses showed the random and interconnected porosity of the CaP glass 
microspheres with a wide distribution of pore sizes (Figs. 1a and 1b). Non-porous 
glass microspheres are also shown in Fig 1c. 
  Fig. 1. a) SEM image showing the as-synthesized porous CaP glass microspheres 
(125-200 µm); b) Detail of the interconnected porosity of the glass microspheres; c) 
Non-porous CaP glass microspheres (60-125 µm). 
Density measurements indicated that the absolute density of the CaP glass 
microspheres was 2.52 ± 0.02 g.cm-3 and the apparent density was 0.70 ± 0.05 g.cm-
3. The calculated porosity of the microspheres using Eq 1 was found to be 75 ± 3%, 
which was very similar to the porosity value obtained for these porous microspheres 
by mercury porosimetry (76±5%) previously reported by Hossain et al., 2018.18 
3.2. Paste characteristics 
CaP glass microsphere pastes extruded through a needle formed with and without 
excipient are shown in Fig. 2.  Glass microsphere pastes without excipient were 
extremely difficult to extrude, and during injection developed a filter cake condition in 
which the microspheres interlocked and the surrounding fluid emerged first (Fig. 2a). 
This condition allowed an extrusion of a small amount of paste by using significant 
force (300 N). Better paste consistency and flow enhancement was observed when 
using excipients (XG, MC, and CMC) in DMEM.  It allowed the extrusion of the glass 
microsphere paste through small syringes (1 and 3 mL) and small needles (14G, 
18G) with forces small enough to allow extrusion by hand (Figs. 2b and 2d). Similar 
flow characteristics were obtained when using saline solution (0.9% NaCl) instead of 
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DMEM. Mixtures containing hyalonuric acid and PEG8000 failed to form an injectable 
paste and were discarded for further study (Figs. 2e and 2f). 
  
Fig. 2. CaP glass microsphere pastes formed a) no excipient, filter cake is formed; b) 
DMEM and XG; c) DMEM and MC; d) DMEM and CMC; e) DMEM and hyaluronic 
acid and f) DMEM and PEG8000 respectively yielding a slurry instead of a paste. In all 
the tests, delivery was performed through a standard 3 mL syringe and a 14G needle 
(8.66 mm and 1.6 mm internal diameter respectively). 
Scanning electron microscope (SEM) images of the CaP glass microspheres were 
collected with and without XG to observe the effect of adding the excipient. The 
images were collected after injection using a 3 mL syringe and a 14G needle (8.66 
mm and 1.6 mm internal diameter respectively).  The injection without XG 
experienced a filter cake condition that contributed to the breakdown of the porous 
CaP glass microspheres (Fig. 3a). However, the use of 40 mg/mL of XG prevented 
the microspheres from damage increasing viscosity and improving the flow of the 
formed paste (Fig. 3b).  High resolution images of the wet paste, injected and 
carefully removed from the 3D lattice (0.95 mm x 0.95 mm x 1.0 mm), showed that 
c)
 a) No excipient  b) XG
 c) MC  d) CMC
 e) Hyaluronic acid f) PEG8000
the CaP glass microspheres remained agglomerated together as a single structure 
with a small amount of XG (Fig. 3c).  
 
Fig. 3. Extruded pastes through a 3 mL syringe and 14G needle a) without XG; b) 
with XG; c) and d) with XG after testing into a 3D osteoporotic lattice (0.95 mm x 
0.95 mm x 1.0 mm dimensions); e)  Porous CaP glass microsphere pastes prepared 
with MC and d) with CMC.  The images were collected in wet pastes without further 
preparation using an environmental SEM. 
Early tests showed that MC and CMC imparted similar flow behavior to the glass 
microsphere pastes as with XG; however, those containing CMC lost structure and 
shape within four hours of the test, making CMC unfavorable candidate for injection 
and delivery.  Therefore, only MC was carried forward for evaluation alongside XG.  
The required concentration of excipient was estimated through viscosity 
measurements with solutions at different concentrations (Figs. 4a and 4b).  Among 
all the solutions, those containing XG showed the highest viscosity at rest; however, 
    500 mm    
a)a) Without XG
  100mm    100 mm  
    100 mm      100 mm   
b) XG
c) XG in 3D lattice d) XG in 3D lattice
    500 mm    
e) MC  f) CMC
the viscosity rapidly decreased with the increase of shear rate presenting a shear 
thinning behavior (Fig. 4a).  At any given shear rate, the solutions with 40 and 60 mg 
XG per mL of DMEM had the highest viscosities; however, when 60 mg/mL was 
used, partial dissolution of XG in the liquid media was observed limiting its 
concentration to below this value. The viscosity also increased progressively with the 
concentration of MC solutions (40, 60 and 80 mg/mL) but to a lower extent than XG 
solutions.  
 
Fig. 4. Viscosity as a function of shear rate of (a)  XG solutions (concentrations 
between 20 and 60 mg/mL), and (b) MC solutions (concentrations between 40 and 
80 mg/mL) in DMEM; (c) Viscosity of pastes formed with CaP glass microspheres 
(0.48g/mL of DMEM) of 125-200 µm in DMEM with either XG or MC as an excipient;  
(d) Viscosity of microsphere pastes using different size range of CaP glass 
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microspheres formed with 40 mg/mL of XG and DMEM solutions. All measurements 
were performed at 20°C. 
 
Similar tests were performed with CaP glass microspheres (0.48g/mL of DMEM, 
125-200 µm) and excipient solutions (either 20, 40, 60 mg/mL of XG, 60 mg/mL of 
MC). Consistently, the results indicated that microsphere pastes containing XG had 
higher viscosities, in particular at low shear rate forming a solid-like paste at rest 
(Fig. 4c). The best performance was obtained when using 40mg/mL of XG which 
provided excellent injectability and ensured full hydration of the XG (Fig. 4d). 
Nevertheless, the viscoelasticity of glass microsphere pastes consisting of 40 mg/mL 
of XG and 60 mg/mL of MC were further evaluated at 1Hz at 20°C.  The 
viscoelasticity results indicated that the elastic component (G’) dominated between 
0.001 and 10% shear rate in CaP glass microsphere pastes containing 40 mg/mL of 
XG. They had high G’ values (~27000- 29000 Pa, Figs. 5a and 5c) and low phase 
angle values (=10-30° at 20°C) suggesting that XG containing pastes had a strong 
structure (Figs. 5a and 5c). These results were also consistent at 37°C in which the 
elastic component (G’) dominated across low and high frequencies indicating that 
the glass microsphere pastes behaved as a viscoelastic solid-like material (see Figs. 
5b and 5d).  Furthermore, evaluation of the system using 40mg/mL of XG at 20°C 
and 1Hz showed that the linear viscoelastic region extended to a strain of 0.02 %; 
after this value, the structure of the microsphere paste started to change. The solid–
like behavior and higher elasticity make this system very effective as a filler and its 
characteristics were maintained when the system was exposed to 37ºC. 
In contrast, glass microsphere pastes prepared with 60 mg/mL of MC showed low 
stiffness (G’ ~1300-400 Pa, Figs. 6a and 6c) in comparison to XG containing pastes.  
The phase angle ( values were found to be between 20 and 60° indicating a liquid-
like (viscous) behavior (Figs. 6a and 6c).  This performance was even more evident 
at 37°C as the system showed a linear viscoelastic region up to 0.39% in strain in 
comparison to 0.01 % at 20ºC.  This indicated that although the microsphere paste 
prepared with MC could behave as a solid-like material at 20ºC, it may flow at rest 
when exposed to 37ºC. 
In addition, stability of the pastes were evaluated by immersing them in DI water for 
24 hours.  The results indicated that XG pastes hydrated but conserved the shape 
after this time, and even the shape was still visible after 48 hours; however, pastes 
formed with MC flattened after 1 hour of immersion and fully dispersed after the 24 
hour period. 
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Fig. 5. Elastic component G’, viscous component G’’, and phase angle  as a 
function of shear stress for the pastes containing 125-200 µm CaP glass 
microspheres in DMEM and XG evaluated at 1Hz frequency at (a) 20°C and (b) 
37°C. G’, G’’, and  as a function of oscillatory frequency for similar glass 
microsphere pastes at (c) 20°C and (d) 37°C. 
 
Overall, since the role of the carrier medium was to maintain a suspension of the 
glass microspheres (i.e. high viscosity) and then upon delivery the role was to resist 
shear forces to minimize transport away from the delivery site, the viscoelastic 
properties observed with XG proved to be highly beneficial for the flow 
characteristics of the glass microsphere paste, thereby enabling minimally invasive 
treatment opportunities utilizing small needles.  As such, XG was the excipient 
chosen for further investigation.  
  
Fig. 6. Elastic component G’, viscous component G’’, and phase angle () as a 
function of shear stress for the systems composed of microsphere pastes (125-200 
µm) in DMEM and MC at (a) 20°C and (b) 37°C. G’, G’’, and   as a function of 
oscillatory frequency for similar glass microsphere pastes at (c) 20°C and (d) 37°C. 
3.3. CaP glass microsphere paste formulation 
The properties of the microsphere paste were also evaluated by combining porous 
and non-porous CaP glass microspheres of similar size-range together, and by also 
mixing porous microspheres between the two size ranges. The base formulation was 
first formed using the initial formulation for porous CaP glass microspheres (1g of 60-
125 µm or 0.48g 125-200 µm) and mixed with 0.04g of gamma sterilized XG and 1 
mL of DMEM. The amount of porous CaP glass microspheres was systematically 
reduced and replaced by non-porous (solid) glass microspheres to form a paste of 
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similar consistency.  A plot of the weight of porous and non-porous CaP glass 
microspheres to obtain the injectable paste followed an inverse linear relationship in 
which 0.10 g of porous microspheres could be replaced by 0.60 g of non-porous 
microspheres (Figs. 7a and 7b). In all cases, to the right of the hatched box shows 
failure due to a high solid loading and filter pressing, and to the left of the hatched 
box shows the region in which the pastes have poor structure; neither are injectable 
(Fig. 7a) The hatched region indicates a successful combination of porous and non-
porous CaP glass microspheres (Figs. 7a and 7b). 
 
Fig.  7. (a) Established formulations for injectable microsphere pastes using a 
combination of porous and non-porous with particle sizes between 60-125 µm using 
1 mL DMEM and 0.04g gamma sterilized XG; (b) as before but using particle sizes 
0.0 0.5 1.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0 0.5 1.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0 0.5 1.0
0.10
0.15
0.20
0.25
0.30
0.35
Not injectable
Poor structure
N
o
n
-p
o
ro
u
s 
m
ic
ro
sp
h
er
es
 (
g)
Porous: 0.04g
Non-porous: 0.02g
60-125 mm
Not injectable
High load
Porous: 0.02g
Non-porous: 0.04g
125-200 mm
Not injectable
Poor structure
Not injectable
High load
Porous microspheres (g)
1
2
5
-2
0
0
 m
m
Not injectable
Poor structure
Not injectable
High load
a) b) c)
60-125 mm
between 125-200 µm; and (c) porous CaP glass microspheres using a mixture of 
sizes (60-125 µm and 125-200 µm).   
The successful combination achieved with porous two screened glass microsphere 
sizes (60-125 µm and 125-200 µm) CaP glass microspheres is shown in Fig. 7c. The 
established formulations were plotted as a function of solid to liquid ratios (S/L, Fig. 
8).  High S/L (> 1 g/mL) were achieved by using a higher proportion of non-porous 
glass microspheres regardless the size range used; however, the formulations with 
only porous CaP glass microspheres for the inclusion of stem cells will yield lower 
S/L (Fig. 8a). 
 
 
Fig. 8 Injectable formulations containing porous and non-porous CaP glass 
microspheres as a function of the S/L ratio (g/mL of solution); a) low S/L ratios (0.4 to 
1.3 g/mL) obtained mainly through the combination of porous microspheres; b) high 
ratios (1.5 to 3.0 g/mL) obtained when non-porous spheres are introduced in the 
formulation. 
3.4. Injection pressure 
The pressures for extrusion of microsphere pastes containing XG, CaP (0.48 g, 125-
200 µm)  and DMEM (1 mL), were quantified between 0.3 and 0.5 MPa using syringes 
of 3, 10 and 20 mL (Fig. 9a). Similar pressures (< ~0.4 MPa) were required to extrude 
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pastes of all formulations tested, and even when using different range size of 
microspheres (Figs. 9b-9d).  These pressures are low enough to inject the pastes by 
hand without any need of a special device to aid with the pressure of system. The low 
pressures required to extrude the pastes were only possible with the addition of XG to 
the mixture, without XG the pressures reached 300MPa to extrude 30% of the paste 
before the syringe failed. A more detailed discussion regarding pressures as a function 
of load are not applicable to the glass pastes studied in this work because the material 
is not homogeneous in size and the microspheres have different porosities; these 
factors make a different structure in every batch.  Nevertheless, the use of XG made 
possible to reduce the pressures to inject by hand without noticing a difference in 
behavior during injection acting as a modifier of the rheological properties of the CaP 
glass. 
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Fig.  9. (a) Total pressure required to extrude the microsphere paste using 0.48g/mL 
and 125-200 µm CaP glass microspheres through 3, 10 and 20 mL syringes and a 
14G needle; in all three cases the pressures were below 0.5 MPa; (b) total pressure 
to extrude porous and non-porous microsphere pastes  (60-125 µm) using 3 mL 
syringes; c) total pressure required to extrude porous microsphere pastes (60-125 
µm and 125-200 µm) using 3 mL syringes; d) total pressure required to extrude 
porous and non-porous microsphere pastes (125-200 µm) using 3 mL syringes. 
4. Discussion 
Recent developments in bone regeneration have shifted towards orthobiologics, 
where one of the approaches explores the use of cell therapy treatments which 
involves the utilization of novel emerging biomaterials with the capability to 
accommodate stem cells, whilst also contributing essential elements for bone 
formation and repair.36,37 Porous microspheres constitute an effective material to fulfil 
these needs and tunable porous CaP glass microspheres have recently been 
produced for the first time.18  As-synthesized and mixed with simple DMEM, these 
porous microspheres are not injectable as they require high forces (>300N) for 
extrusion and the formation of a filter cake within the injection device does not allow 
delivery of the intended formulation.  Addition of xanthan gum (XG) to the CaP glass 
microsphere paste dispersed in liquid media (either DMEM or saline solution), 
increased the viscosity and imparted elasticity to form a paste that ultimately improved 
its flow characteristics and facilitated injection and delivery.  This improvement was 
maintained at both room and body temperature.  Similarly, methyl cellulose (MC) and 
carboxyl methyl cellulose (CMC) also improved the flow properties of the glass 
microsphere paste, however, the resulting paste was found to behave predominantly 
as a viscous-liquid, prone to dispersion from the place of injection, in particular at body 
temperature (Figs. 5c and 5d). Previous studies have demonstrated that viscosity is a 
key factor that determines flow of filling materials,38-41 however this study showed that 
the increase of viscosity alone does not improve the flow behavior of porous CaP glass 
microspheres.  Other factors such as particle size distribution and the intrinsic surface 
area can also affect the viscosity and the flow characteristics.  
The glass microsphere paste formulations prepared with XG were able to be 
extruded from standard syringes in the range of 3 to 20 mL using relatively small 
diameter needles (14G and 18G). Furthermore, the addition of XG into the system 
prevented the CaP glass microspheres from damage during delivery (Figs 3c and 
3d) as the injection pressure was reduced to less than 0.5 MPa. The optimum 
behavior was achieved when using 40 mg/mL of XG; below this concentration the 
microsphere-media mixture showed poor structure and showed formation of a filter 
cake in common with the formulation nit including XG.   
The formation of a paste prepared with porous CaP glass microspheres was greatly 
affected by the presence of non-porous microspheres. As such, the formulations to 
make an injectable paste were restricted to specific proportions between non-porous 
and porous CaP glass microspheres.  Injectable formulations which combined 
porous and non-porous CaP glass microspheres followed a linear relationship given 
by massnon-porous= 6*massporous (within 0.02 g in weight).  This relationship was 
related to the density of the particles as the volume fraction was maintained constant 
(i.e., the density of the non-porous particles is ~ 6 times higher than the porous 
particles). The porous CaP glass microspheres allowed greater fluid volume to be 
carried (i.e. within the internal structure of the particles) whilst maintaining an 
efficient formulation for delivery (i.e. both injectable and with structural properties in 
absence of flow). The presence of non-porous CaP glass microspheres in the 
formulation increased the solid to liquid ratio from 1.0 g/mL to 3.0 g/mL (i.e. 10% 
non-porous 1.5 g/mL; 20% non-porous 2.0 g/mL; 40% non-porous 3.0 g/mL).  This is 
important because non-porous CaP glass contributes to a higher concentration of 
biotherapeutic ions (e.g., Ca2+, Mg2+) that could potentially play important roles 
during the bone repair and regeneration process.42  This also allows tuning of the 
overall formulation to provide structural rigidity and a source of ions whilst carrying 
cells (and or other biological entities), depending on the particular end application.  In 
addition, having non-porous CaP glass microspheres as a result of a manufacturing 
process, no more than 8% from the total mass of the batch of microspheres should 
be solid to be injectable. 
The size range of the particles also affected the formulation of the microsphere 
pastes. For 1mL of either DMEM a successful composition consisting of 1g of 60-125 
µm or 0.48g of 125-200 µm of CaP glass microspheres was required to maintain the 
ideal consistency of the paste for delivery.  This indicated that the larger CaP glass 
microspheres required twice the volume of solution to form the paste than the 
smaller microspheres, suggesting that increasing the proportion of larger 
microspheres in the formulation, would decrease the S/L ratios.  Conversely, the use 
of only porous microspheres would yield lower solid to liquid ratios. 
During the injection process, the pressure rapidly increased at the beginning of the 
injection; however, it was maintained below 0.5 N/mm2 providing good flow, even 
when using large syringes (10-20 mL) and small needles (14G and 18G). The pressure 
profiles of injecting CaP glass microsphere pastes evaluated here, showed the same 
trend as those presented in previous works for irregular shaped calcium phosphate 
materials, in which the pressure rapidly increased reaching a steady state as the 
extrusion of the paste progressed.43   Our study demonstrated that the increase of 
viscosity does not necessarily improve the flow characteristics of the porous CaP glass 
microsphere, at least with their composition and morphology,  but particle size, surface 
area and in particular, the elastic component imparted by XG played a significant role. 
This is contradictory to the reported injectability of  similar CaP glass materials in which 
an increase in viscosity increases injectability;43 however, in this work that behavior 
was not observed as demonstrated with our results using MC in which only the 
viscosity is increased.  Instead, the elasticity and viscosity of XG allowed the porous 
CaP microspheres to form an injectable paste.  These characteristics in-turn impart 
restrictions on the S/L ratio restricting the formulation.  Overall, the addition of XG in 
the optimal concentration produced a robust CaP microsphere paste, which could 
deliver microspheres without damage easily via simple injection through small < 2mm 
inner diameter needles.  
5. Conclusions 
Porous and non-porous CaP glass microspheres synthesized for cell-based bone 
regeneration treatment were found to be injectable when excipient was added. From 
the excipients evaluated, xanthan gum provided the best flow characteristics 
compared to methyl cellulose and carboxyl methylcellulose at room and body 
temperature. The extrusion of paste was achieved using 14G and 18G needles and 
syringe in sizes from 3 to 20 mL.  The use of xanthan gum protected the porous CaP 
glass microspheres from damage during injection due to its viscoelastic properties. 
Formulation of porous CaP glass microspheres for delivery in paste form must follow 
specific ratios and adjustments must be made when non-porous microspheres are 
present. Flow characteristics of the glass microsphere paste in media (i.e. DMEM or 
saline solution) depend on particle size, surface area, S/L ratio, and concentration of 
excipient that provides viscoelastic properties.  Overall, a formulation with xanthan 
gum as an excipient to porous CaP glass microspheres allowed for effortless delivery 
through narrow diameter needles.  
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